Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech outlines a post-GSK plan to operate without going to the capital markets while refocusing on internal development.
You may also be interested in...
Oncology Candidates Stream From Exelixis Discovery Platform
Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.
Oncology Candidates Stream From Exelixis Discovery Platform
Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.